|
|
|
53. Lactoferrin-bearing gold nanocages for gene delivery in prostate cancer cells. Almowalad, J., Somani, S., Laskar, P., Meewan, J., Tate, R.J., Mullin, M., Dufès C., International Journal of Nanomedicine (2021) (in press).
52. Tumor regression after intravenous administration of plumbagin entrapped in transferrin-conjugated, lipid-polymer hybrid nanoparticles. Sakpakdeejaroen, I., Somani, S., Laskar, P., Mullin, M., Dufès C., International Journal of Nanomedicine 16 (2021) 2615-2631 (link to the full article).
51. Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells Laskar, P., Somani, S., Mullin, M., Tate, R.J., Warzecha, M., Bowering, D., Keating, P., Irving, C., Leung, H. Y., Dufès C., Biomaterials Science 9(4) (2021) 1431-1448 (link to the full article).
50. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. Rushworth, L.K., Patel, R., Hewit, K., James, D., Munnings-Tomes, S., Straube, A., Shanks, E., Somani, S., Dufès, C., Leung, H.Y., British Journal of Cancer, 122 (4) (2020) 517-527 (link to the full article).
49. Anti-tumor activity of intravenously administered plumbagin entrapped in targeted nanoparticles. Sakpakdeejaroen, I., Somani, S., Laskar, P., Irving, C., Mullin, M., Dufès, C., Journal of Biomedical Nanotechnology, 16 (1) (2020) 85-100 (link to the full article).
48. Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells. Laskar, P., Somani, S., Campbell, S.J., Mullin, M., Keating, P., Tate, R.J., Irving, C., Leung, H.Y., Dufès, C., Nanoscale, 11 (42) (2019) 20058-20071 (link to the full article).
47. On the issue of transparency and reproducibility in nanomedicine. H.S. Leong, K.S. Butler, C.J. Brinker, M. Azzawi, S. Conlan, C. Dufès, A. Owen, S. Rannard, C. Scott, C. Chen, M.A. Dobrovolskaia, S.V. Kozlov, A. Prina-Mello, R. Schmid, P. Wick, F. Caputo, P. Boisseau, R.M. Crist, S.E. McNeil, B. Fadeel, L. Tran, S.F. Hansen, N.B. Hartmann, L.P.W. Clausen, L.M. Skjolding, A. Baun, M. Ågerstrand, Z. Gu, D.A. Lamprou, C. Hoskins, L. Huang, W. Song, H. Cao, X. Liu, K.D. Jandt, W. Jiang, B.Y.S. Kim, K.E. Wheeler, A.J. Chetwynd, I. Lynch, S.M. Moghimi, A. Nel, T. Xia, P.S. Weiss, B. Sarmento, J. das Neves, H.A. Santos, L. Santos, S. Mitragotri, S. Little, D. Peer, M.M. Amiji, M.J. Alonso, A. Petri-Fink, S. Balog, A. Lee , B. Drasler, B. Rothen-Rutishauser, S. Wilhelm, H. Acar, R.G. Harrison, C. Mao, P. Mukherjee, R. Ramesh, L.R. McNally, S. Busatto, J. Wolfram, P. Bergese, M. Ferrari, R.H. Fang, L. Zhang, J. Zheng, C. Peng, B. Du, M. Yu, D.M. Charron, G. Zheng, C. Pastore, Nature Nanotechnology, 14 (2019) 626-635 (link to the full article).
46. Transferrin-targeted liposomes entrapping plumbagin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Laskar, P., Mullin, M., Dufès C., Journal of Interdisciplinary Nanomedicine, 4(2) (2019) 54-71 (link to the full article).
45. Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Mullin, M., Dufès C., Journal of Liposome Research, 5 (2019) 1-8 (link to the full article).
44. Redox-sensitive, cholesterol-bearing PEGylated poly(propylenimine)-based dendrimersomes for drug and gene delivery to the cancer cells. Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering D., Warzecha, M., Leung, H.Y., Dufès, C. (2018) Nanoscale, 10 (2018) 22830-22847 (link to the full article).
43. Challenges and Opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Maniam, G., Mai, C. W., Zulfekeli, M., Dufès, C., Tan, D.M.Y., Fu, J.Y. (2018) Frontiers in Pharmacology, 9 (2018) 1358 (link to the full article).
42. Targeted non-viral gene therapy in prostate cancer. Altwaijry, N., Somani, S., Dufes, C. (2018) International Journal of Nanomedicine, 13, 5753-5767 (link to the full article).
41. Proof of concept studies for siRNA delivery by cationic non-ionic surfactant vesicles (CN): In vitro and in vivo protein knockdown. Obeid, M. A., Tate, R. J., Mullen, A. B., Dufès, C., Somani, S., Ferro, V. A. (2018) Journal of Liposome Research, 8, 1-27 (link to the full article).
40. PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells. Somani, S., Laskar, P., Altwaijry, N., Kewcharoenwong, P., Irving, C., Robb, G., Pickard, B.S.,Dufès, C (2018) Scientific Reports, 8, 9410 (link to the full article).
39. Regression of prostate tumours after intravenous administratin of lactoferrin bearing polypropylenimine dendriplexes encoding TNF-alpha, TRAIL and interleukin-12. Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha M., Mackenzie, G.R., Leung, H.Y., Dufès, C. (2018) Drug delivery, 25(1) 679-289 (link to the full article).
38. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol Karim, R., Somani, S., Al Robaian, M., Mullin, M., Amor, R., McConnell G.,Dufès, C. Journal of Controlled Release 246, 79-87 (link to the full article).
37. Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex Somani, S., Robb, G., Pickard, B. S. & Dufes, C. Journal of Controlled Release. 217, 235-242 (link to the full article).
36. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes Lim, L. Y., Koh, P. Y., Somani, S., Al Robaian, M., Karim, R., Yean, Y. L., Mitchell, J., Tate, R. J., Edrada-Ebel, R., Blatchford, D. R., Mullin, M., Dufès, C. Nanomedicine: Nanotechnology, Biology and Medicine 11 (2015) 1445-1454 (link to the full article).
35. Transferrin-bearing dendrimers for cancer therapy: an update Somani, S., Dufes, C. Nanomedicine 10 (14) (2015) 2125-21273 (link to the full article).
34. Anti-cancer efficacy of intravenously administered tumor-targeted vesicles entrapping tocotrienol Fu, J. Y., Dufès, C. Pharmaceutical Nanotechnology 2 (4) (2015) 172-181 (link to the full article).
33. Applications of dendrimers for brain delivery and cancer therapy Somani, S., Dufès, C. Nanomedicine 9 (15) (2014) 2403-2414 (link to the full article).
32. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain Somani, S., Blatchford, D. R., Millington, O., Stevenson, M. L., Dufès, C. Journal of Controlled Release 188 (2014) 78-86 (link to the full article).
31. E2F1 drives chemotherapeutic drug resistance via ABCG2 Rosenfeldt, M., Bell, L., Long, J., O'Prey, J., Nixon, C., Roberts, F., Dufès, C., Ryan, K. Oncogene 33 (2014) 4164-4172 (link to the full article).
30. Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight dependent transport processes El-Hammadi, M. M., MacLellan, S., Dufès, C., Holmes, W. M., Condon, B., Uchegbu, I. F., Schatzlein, A. G. Pharmaceutical Nanotechnology 2 (3) (2014) 129-137 (link to the full article).
29. The application of nanotechnology in medicine: treatment and diagnostics Owain, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J., Katti, K., Sokolov, K., Mazza, M., Fontaine, O., Rannard, S., Stone, V. Nanomedicine 9 (9) (2014) 1291-1294 (link to the full article).
28. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas Al Robaian, M. M. M., Chiam, K. Y., Blatchford, D., Dufès, C. Nanomedicine 9 (4) (2014) 421-434 (link to the full article).
27. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Dufès, C., Al Robaian, M. M. M., Somani, S. Therapeutic Delivery 4 (5) (2013) 629-640 (link to the full article).
26. Dendrimer-Based Drug Delivery Systems: From Theory to Practice Edited by Yiyun Cheng Dufès, C. ChemMedChem. 8 (2) (2013) 336 (link to the full article).
25. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration Lemarié, F., Chang, C. W., Blatchford, D., Amor, R., Norris, G., Tetley, L., McConnell, G., Dufès, C. Nanomedicine 8 (2) (2013) 181-192 (link to the full article).
24. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system Lemarié, F., Croft, D., Tate, R., Ryan, K. M., Dufès, C. Biomaterials 33 (2012) 2701-2709 (link to the full article).
23. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy Wilkinson, S., Croft, D., O’Prey, J., Meedendorp, A., O’Prey, M., Dufès, C., Ryan, K. M. Autophagy 7 (11) (2011) 1295-1301 (link to the full article).
22. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex Aldawsari, H. M., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L., Dufès, C. Biomaterials. 32 (25) (2011) 5889-5899 (link to the full article).
21. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration Fu, J. Y., Zhang, W., Blatchford, D., Tetley, L., Mcconnell, G., Dufès, C. Journal of Controlled Release 154 (1) (2011) 20-26 (link to the full article).
20. Drug and gene delivery systems Dufès, C. & Watson, D. G. (ed.) Pharmaceutical Chemistry. First ed. , 2011, p. 581-590.
19. Brain delivery of peptides and proteins Dufès, C. Peptide and protein delivery. van der Walle, C. (ed.). First ed. , 2011, Vol. 1, p. 105-122.
18. Delivery of the vitamin E compound tocotrienol to cancer cells Dufès, C. Therapeutic Delivery 2 (11) (2011) 1385-1389 (link to the full article).
17. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polyethylenimine polyplex Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L., Dufès, C. Nanomedicine: Nanotechnology, Biology and Medicine 7 (5) (2011) 815-823 (link to the full article).
16. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA Koppu, S., Oh, Y. J., Edrada-Ebel, R., Blatchford, D. R., Tetley, L., Tate, R., Dufès, C. Journal of Controlled Release 143 (2) (2010) 215-221 (link to the full article).
15. Enhanced transfection efficacy of polyethylenimine by surface modification with arginine, lysine, and leucine Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Dufès, C. Controlled Release Society Newsletter 27 (6) (2010) 12-14.
14. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles Fu, J. Y., Blatchford, D. R., Tetley, L., Dufès, C. Journal of Controlled Release 140 (2) (2009) 95-99 (link to the full article).
13. Polymers and dendrimers for gene delivery in gene therapy Uchegbu, I. F., Dufès, C. M., Kan, P. L., Schätzlein, A. G., Templeton, N. S. (ed.) Gene and cell therapy: therapeutic mechanisms and strategies 3rd ed. , 2008, p. 321-339.
12. High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil Holmes, W. M., Maclellan, S., Condon, B., Dufès, C., Evans, T. R. J., Uchegbu, I. F., Schätzlein, A. G. Physics in Medicine and Biology 53 (2008) 505-513 (link to the full article).
11. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo Bell, H. S., Dufès, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., Schätzlein, A. G., Vousden, K. H., Ryan, K. M. Journal of Clinical Investigation 117 (4) (2007) 1008-1018 (link to the full article).
10. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Qu, X., Khutoryanskiy, V. V., Stewart, A., Rahman, S., Papahadjopoulos-Sternberg, B., Dufès, C., McCarthy, D., Wilson, C. G., Lyons, R., Carter, K. C., Schätzlein, A., Uchegbu, I. F. Biomacromolecules 7 (12) (2006) 3452-3459 (link to the full article).
9. Dendrimers in gene delivery Dufès, C., Uchegbu, I. F., Schätzlein, A. G. Advanced Drug Delivery Reviews 57 (15) (2005) 2177-2202 (link to the full article).
8. Preferential liver gene expression with polypropylenimine dendrimers Schätzlein, A. G., Zinselmeyer, B. H., Elouzi, A., Dufès, C., Chim, Y. T. A., Roberts, C. J., Davies, M. C., Munro, A., Gray, A. I., Uchegbu, I. F. Journal of Controlled Release 101 (2005) 247-258 (link to the full article).
7. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors Dufès, C., Keith, W. N., Bilsland, A., Proutski, I., Uchegbu, I. F., Schätzlein, A. G. Cancer Research 65 (18) (2005) 8079-8084 (link to the full article).
6. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles Dufès, C., Muller, J-M., Couet, W., Olivier, J-C., Uchegbu, I. F., Schätzlein, A. G. Pharmaceutical Research 21 (1) (2004) 101-7 (link to the full article).
5. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain Dufès, C., Gaillard, F., Uchegbu, I. F., Schätzlein, A. G., Olivier, J-C., Muller, J-M. International Journal of Pharmaceutics 285 (2004) 77-85 (link to the full article).
4. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats Dufès, C., Olivier, J-C., Gaillard, F., Gaillard, A., Couet, W., Muller, J-M. International Journal of Pharmaceutics 255 (2003) 87-97 (link to the full article).
3. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro Dufès, C., Alleaume, C., Montoni, A., Olivier, J-C., Muller, J-M. Journal of Molecular Neuroscience 21 (2) (2003) 91-102 (link to the full article).
2. Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery McPhail, D., Tetley, L., Dufès, C., Uchegbu, I. F. International Journal of Pharmaceutics 200 (1) (2000) 73-86 (link to the full article).
1. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting Dufès, C., Schätzlein, A. G., Tetley, L., Gray, A. I., Watson, D. G., Olivier, J. C., Couet, W., Uchegbu, I. F. Pharmaceutical Research 17 (10) (2000) 1250-1258 (link to the full article).
52. Tumor regression after intravenous administration of plumbagin entrapped in transferrin-conjugated, lipid-polymer hybrid nanoparticles. Sakpakdeejaroen, I., Somani, S., Laskar, P., Mullin, M., Dufès C., International Journal of Nanomedicine 16 (2021) 2615-2631 (link to the full article).
51. Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells Laskar, P., Somani, S., Mullin, M., Tate, R.J., Warzecha, M., Bowering, D., Keating, P., Irving, C., Leung, H. Y., Dufès C., Biomaterials Science 9(4) (2021) 1431-1448 (link to the full article).
50. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. Rushworth, L.K., Patel, R., Hewit, K., James, D., Munnings-Tomes, S., Straube, A., Shanks, E., Somani, S., Dufès, C., Leung, H.Y., British Journal of Cancer, 122 (4) (2020) 517-527 (link to the full article).
49. Anti-tumor activity of intravenously administered plumbagin entrapped in targeted nanoparticles. Sakpakdeejaroen, I., Somani, S., Laskar, P., Irving, C., Mullin, M., Dufès, C., Journal of Biomedical Nanotechnology, 16 (1) (2020) 85-100 (link to the full article).
48. Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells. Laskar, P., Somani, S., Campbell, S.J., Mullin, M., Keating, P., Tate, R.J., Irving, C., Leung, H.Y., Dufès, C., Nanoscale, 11 (42) (2019) 20058-20071 (link to the full article).
47. On the issue of transparency and reproducibility in nanomedicine. H.S. Leong, K.S. Butler, C.J. Brinker, M. Azzawi, S. Conlan, C. Dufès, A. Owen, S. Rannard, C. Scott, C. Chen, M.A. Dobrovolskaia, S.V. Kozlov, A. Prina-Mello, R. Schmid, P. Wick, F. Caputo, P. Boisseau, R.M. Crist, S.E. McNeil, B. Fadeel, L. Tran, S.F. Hansen, N.B. Hartmann, L.P.W. Clausen, L.M. Skjolding, A. Baun, M. Ågerstrand, Z. Gu, D.A. Lamprou, C. Hoskins, L. Huang, W. Song, H. Cao, X. Liu, K.D. Jandt, W. Jiang, B.Y.S. Kim, K.E. Wheeler, A.J. Chetwynd, I. Lynch, S.M. Moghimi, A. Nel, T. Xia, P.S. Weiss, B. Sarmento, J. das Neves, H.A. Santos, L. Santos, S. Mitragotri, S. Little, D. Peer, M.M. Amiji, M.J. Alonso, A. Petri-Fink, S. Balog, A. Lee , B. Drasler, B. Rothen-Rutishauser, S. Wilhelm, H. Acar, R.G. Harrison, C. Mao, P. Mukherjee, R. Ramesh, L.R. McNally, S. Busatto, J. Wolfram, P. Bergese, M. Ferrari, R.H. Fang, L. Zhang, J. Zheng, C. Peng, B. Du, M. Yu, D.M. Charron, G. Zheng, C. Pastore, Nature Nanotechnology, 14 (2019) 626-635 (link to the full article).
46. Transferrin-targeted liposomes entrapping plumbagin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Laskar, P., Mullin, M., Dufès C., Journal of Interdisciplinary Nanomedicine, 4(2) (2019) 54-71 (link to the full article).
45. Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Mullin, M., Dufès C., Journal of Liposome Research, 5 (2019) 1-8 (link to the full article).
44. Redox-sensitive, cholesterol-bearing PEGylated poly(propylenimine)-based dendrimersomes for drug and gene delivery to the cancer cells. Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering D., Warzecha, M., Leung, H.Y., Dufès, C. (2018) Nanoscale, 10 (2018) 22830-22847 (link to the full article).
43. Challenges and Opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Maniam, G., Mai, C. W., Zulfekeli, M., Dufès, C., Tan, D.M.Y., Fu, J.Y. (2018) Frontiers in Pharmacology, 9 (2018) 1358 (link to the full article).
42. Targeted non-viral gene therapy in prostate cancer. Altwaijry, N., Somani, S., Dufes, C. (2018) International Journal of Nanomedicine, 13, 5753-5767 (link to the full article).
41. Proof of concept studies for siRNA delivery by cationic non-ionic surfactant vesicles (CN): In vitro and in vivo protein knockdown. Obeid, M. A., Tate, R. J., Mullen, A. B., Dufès, C., Somani, S., Ferro, V. A. (2018) Journal of Liposome Research, 8, 1-27 (link to the full article).
40. PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells. Somani, S., Laskar, P., Altwaijry, N., Kewcharoenwong, P., Irving, C., Robb, G., Pickard, B.S.,Dufès, C (2018) Scientific Reports, 8, 9410 (link to the full article).
39. Regression of prostate tumours after intravenous administratin of lactoferrin bearing polypropylenimine dendriplexes encoding TNF-alpha, TRAIL and interleukin-12. Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha M., Mackenzie, G.R., Leung, H.Y., Dufès, C. (2018) Drug delivery, 25(1) 679-289 (link to the full article).
38. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol Karim, R., Somani, S., Al Robaian, M., Mullin, M., Amor, R., McConnell G.,Dufès, C. Journal of Controlled Release 246, 79-87 (link to the full article).
37. Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex Somani, S., Robb, G., Pickard, B. S. & Dufes, C. Journal of Controlled Release. 217, 235-242 (link to the full article).
36. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes Lim, L. Y., Koh, P. Y., Somani, S., Al Robaian, M., Karim, R., Yean, Y. L., Mitchell, J., Tate, R. J., Edrada-Ebel, R., Blatchford, D. R., Mullin, M., Dufès, C. Nanomedicine: Nanotechnology, Biology and Medicine 11 (2015) 1445-1454 (link to the full article).
35. Transferrin-bearing dendrimers for cancer therapy: an update Somani, S., Dufes, C. Nanomedicine 10 (14) (2015) 2125-21273 (link to the full article).
34. Anti-cancer efficacy of intravenously administered tumor-targeted vesicles entrapping tocotrienol Fu, J. Y., Dufès, C. Pharmaceutical Nanotechnology 2 (4) (2015) 172-181 (link to the full article).
33. Applications of dendrimers for brain delivery and cancer therapy Somani, S., Dufès, C. Nanomedicine 9 (15) (2014) 2403-2414 (link to the full article).
32. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain Somani, S., Blatchford, D. R., Millington, O., Stevenson, M. L., Dufès, C. Journal of Controlled Release 188 (2014) 78-86 (link to the full article).
31. E2F1 drives chemotherapeutic drug resistance via ABCG2 Rosenfeldt, M., Bell, L., Long, J., O'Prey, J., Nixon, C., Roberts, F., Dufès, C., Ryan, K. Oncogene 33 (2014) 4164-4172 (link to the full article).
30. Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight dependent transport processes El-Hammadi, M. M., MacLellan, S., Dufès, C., Holmes, W. M., Condon, B., Uchegbu, I. F., Schatzlein, A. G. Pharmaceutical Nanotechnology 2 (3) (2014) 129-137 (link to the full article).
29. The application of nanotechnology in medicine: treatment and diagnostics Owain, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J., Katti, K., Sokolov, K., Mazza, M., Fontaine, O., Rannard, S., Stone, V. Nanomedicine 9 (9) (2014) 1291-1294 (link to the full article).
28. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas Al Robaian, M. M. M., Chiam, K. Y., Blatchford, D., Dufès, C. Nanomedicine 9 (4) (2014) 421-434 (link to the full article).
27. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Dufès, C., Al Robaian, M. M. M., Somani, S. Therapeutic Delivery 4 (5) (2013) 629-640 (link to the full article).
26. Dendrimer-Based Drug Delivery Systems: From Theory to Practice Edited by Yiyun Cheng Dufès, C. ChemMedChem. 8 (2) (2013) 336 (link to the full article).
25. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration Lemarié, F., Chang, C. W., Blatchford, D., Amor, R., Norris, G., Tetley, L., McConnell, G., Dufès, C. Nanomedicine 8 (2) (2013) 181-192 (link to the full article).
24. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system Lemarié, F., Croft, D., Tate, R., Ryan, K. M., Dufès, C. Biomaterials 33 (2012) 2701-2709 (link to the full article).
23. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy Wilkinson, S., Croft, D., O’Prey, J., Meedendorp, A., O’Prey, M., Dufès, C., Ryan, K. M. Autophagy 7 (11) (2011) 1295-1301 (link to the full article).
22. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex Aldawsari, H. M., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L., Dufès, C. Biomaterials. 32 (25) (2011) 5889-5899 (link to the full article).
21. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration Fu, J. Y., Zhang, W., Blatchford, D., Tetley, L., Mcconnell, G., Dufès, C. Journal of Controlled Release 154 (1) (2011) 20-26 (link to the full article).
20. Drug and gene delivery systems Dufès, C. & Watson, D. G. (ed.) Pharmaceutical Chemistry. First ed. , 2011, p. 581-590.
19. Brain delivery of peptides and proteins Dufès, C. Peptide and protein delivery. van der Walle, C. (ed.). First ed. , 2011, Vol. 1, p. 105-122.
18. Delivery of the vitamin E compound tocotrienol to cancer cells Dufès, C. Therapeutic Delivery 2 (11) (2011) 1385-1389 (link to the full article).
17. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polyethylenimine polyplex Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L., Dufès, C. Nanomedicine: Nanotechnology, Biology and Medicine 7 (5) (2011) 815-823 (link to the full article).
16. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA Koppu, S., Oh, Y. J., Edrada-Ebel, R., Blatchford, D. R., Tetley, L., Tate, R., Dufès, C. Journal of Controlled Release 143 (2) (2010) 215-221 (link to the full article).
15. Enhanced transfection efficacy of polyethylenimine by surface modification with arginine, lysine, and leucine Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Dufès, C. Controlled Release Society Newsletter 27 (6) (2010) 12-14.
14. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles Fu, J. Y., Blatchford, D. R., Tetley, L., Dufès, C. Journal of Controlled Release 140 (2) (2009) 95-99 (link to the full article).
13. Polymers and dendrimers for gene delivery in gene therapy Uchegbu, I. F., Dufès, C. M., Kan, P. L., Schätzlein, A. G., Templeton, N. S. (ed.) Gene and cell therapy: therapeutic mechanisms and strategies 3rd ed. , 2008, p. 321-339.
12. High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil Holmes, W. M., Maclellan, S., Condon, B., Dufès, C., Evans, T. R. J., Uchegbu, I. F., Schätzlein, A. G. Physics in Medicine and Biology 53 (2008) 505-513 (link to the full article).
11. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo Bell, H. S., Dufès, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., Schätzlein, A. G., Vousden, K. H., Ryan, K. M. Journal of Clinical Investigation 117 (4) (2007) 1008-1018 (link to the full article).
10. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Qu, X., Khutoryanskiy, V. V., Stewart, A., Rahman, S., Papahadjopoulos-Sternberg, B., Dufès, C., McCarthy, D., Wilson, C. G., Lyons, R., Carter, K. C., Schätzlein, A., Uchegbu, I. F. Biomacromolecules 7 (12) (2006) 3452-3459 (link to the full article).
9. Dendrimers in gene delivery Dufès, C., Uchegbu, I. F., Schätzlein, A. G. Advanced Drug Delivery Reviews 57 (15) (2005) 2177-2202 (link to the full article).
8. Preferential liver gene expression with polypropylenimine dendrimers Schätzlein, A. G., Zinselmeyer, B. H., Elouzi, A., Dufès, C., Chim, Y. T. A., Roberts, C. J., Davies, M. C., Munro, A., Gray, A. I., Uchegbu, I. F. Journal of Controlled Release 101 (2005) 247-258 (link to the full article).
7. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors Dufès, C., Keith, W. N., Bilsland, A., Proutski, I., Uchegbu, I. F., Schätzlein, A. G. Cancer Research 65 (18) (2005) 8079-8084 (link to the full article).
6. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles Dufès, C., Muller, J-M., Couet, W., Olivier, J-C., Uchegbu, I. F., Schätzlein, A. G. Pharmaceutical Research 21 (1) (2004) 101-7 (link to the full article).
5. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain Dufès, C., Gaillard, F., Uchegbu, I. F., Schätzlein, A. G., Olivier, J-C., Muller, J-M. International Journal of Pharmaceutics 285 (2004) 77-85 (link to the full article).
4. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats Dufès, C., Olivier, J-C., Gaillard, F., Gaillard, A., Couet, W., Muller, J-M. International Journal of Pharmaceutics 255 (2003) 87-97 (link to the full article).
3. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro Dufès, C., Alleaume, C., Montoni, A., Olivier, J-C., Muller, J-M. Journal of Molecular Neuroscience 21 (2) (2003) 91-102 (link to the full article).
2. Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery McPhail, D., Tetley, L., Dufès, C., Uchegbu, I. F. International Journal of Pharmaceutics 200 (1) (2000) 73-86 (link to the full article).
1. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting Dufès, C., Schätzlein, A. G., Tetley, L., Gray, A. I., Watson, D. G., Olivier, J. C., Couet, W., Uchegbu, I. F. Pharmaceutical Research 17 (10) (2000) 1250-1258 (link to the full article).
